Roche: Jefferies confirms rating
(CercleFinance.com) - This morning Regeneron announced the first data from an analysis of an uninterrupted Phase 1/2/3 trial of its investigational REGN-COV2 antibody cocktail showing that it reduces viral load and the time to relieve symptoms in outpatients with Covid-19.
Following this announcement, Jefferies confirms its buy rating on the share with a target price of 385 Swiss francs (20% upside).
"These data suggest this therapy could provide an option to help bridge until vaccines are available," the broker says.
"Next steps include meeting with FDA: Regeneron plans to share these data with the FDA imminently, and while it is encouraged it remains to be determined if the dataset is deemed sufficient by FDA to receive Emergency Use Authorization," it adds.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
Following this announcement, Jefferies confirms its buy rating on the share with a target price of 385 Swiss francs (20% upside).
"These data suggest this therapy could provide an option to help bridge until vaccines are available," the broker says.
"Next steps include meeting with FDA: Regeneron plans to share these data with the FDA imminently, and while it is encouraged it remains to be determined if the dataset is deemed sufficient by FDA to receive Emergency Use Authorization," it adds.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.